EGFR and non-small cell lung carcinoma: However, more than 50% of EGFR-mutated NSCLC patients using first or second-generation TKIs developed acquired resistance due to gatekeeper T790M point mutation, leading to the development of third-generation TKIs (Andrews Wright and Goss, 2019).